Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features

@article{Guler2010AberrantEO,
  title={Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features},
  author={Gulnur Guler and Ciğdem Himmetoğlu and Rafael E. Jimenez and Susan M. Geyer and Wenle P. Wang and Stefan Costinean and Robert T. Pilarski and Carl D. Morrison and Dinc Suren and Jianhua Liu and Jingchun Chen and Jyoti Kamal and Charles L. Shapiro and Kay Huebner},
  journal={Breast Cancer Research and Treatment},
  year={2010},
  volume={129},
  pages={421-432}
}
Landmark studies of the status of DNA damage checkpoints and associated repair functions in preneoplastic and neoplastic cells has focused attention on importance of these pathways in cancer development, and inhibitors of repair pathways are in clinical trials for treatment of triple negative breast cancer. Cancer heterogeneity suggests that specific cancer subtypes will have distinct mechanisms of DNA damage survival, dependent on biological context. In this study, status of DNA damage… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Alteration of WWOX in human cancer: a clinical view.

  • Experimental biology and medicine
  • 2015
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The Expression and Clinical Outcome of pCHK2-Thr68 and pCDC25C-Ser216 in Breast Cancer

  • International journal of molecular sciences
  • 2016
VIEW 1 EXCERPT
CITES RESULTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Aberrant luminal progenitors as the candidate target population Breast Cancer Res Treat

E Lim, F Vaillant, +18 authors GJ Lindeman
  • Nat Med
  • 2009

Clinical relevance of the triplenegative breast cancer concept: genetic basis and clinical utility of the concept

SC Linn, LJ Van ‘t Veer
  • Eur J Cancer
  • 2009
VIEW 1 EXCERPT